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Abstract
In many tumor types, where the prognosis was shown to be extremely dismal before, 
immunotherapy is now a new beacon of hope to many patients. Immunotherapy has 
been approved for use in a many different cancers including metastatic melanoma, 
advanced non-small cell lung cancer, metastatic renal cell carcinoma, refractory 
Hodgkin’s lymphoma, metastatic bladder cancer advanced head and neck cancer, and 
the list keeps growing each day. It seems to be generally better tolerated in most patients 
and less toxic compared to what we have seen in different anticancer treatments from 
before. However, the toxicities here are termed immune-related adverse events. There is 
almost no prospective data on these toxicities, and guidelines or recommendations are 
mostly based on symptomatic management from the ongoing clinical trials. Treating 
oncologists need to be aware of the subtleties in presentation and the huge difference 
in the way we mange these side effects. Although most adverse events are low-grade 
and manageable, they have the potential to be life-threatening if not treated promptly. 
In this chapter, we address the different immune-related adverse events relating to the 
organ system they can involve, presentation and symptomatology, general recommen-
dations of management, and individual toxicities. Keywords: immunotherapy, PD-1, 
CTLA-4.
Keywords: immunotherapy, PD-1, CTLA-4, immune-related adverse events, iRAE, 
supportive care
1. Introduction
Immunotherapy has emerged as the utmost oncological advance of 2016 [1]. It encompasses 
the enhancement, suppression, or induction of the body’s own immune system to battle 
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 cancer [1]. There has been a paradigm shift toward immunooncology therapy, and its side 
effects are often referred to as immune-related adverse events (irAEs). These side effects are 
in some cases unique and very different than those associated with chemotherapy or targeted 
drugs. The spectrum of irAEs is typically low-grade and manageable; however, the reporting 
of irAEs is generally suboptimal [2]. Therefore, oncologists should be aware that there is a 
broad range of additional toxicities and side effects that can be both unpredictable and even 
severe in nature. Early recognition of irAEs and aggressive management is crucial to reduce 
morbidity and mortality. Toxicities associated with PD-1 inhibitors are generally less severe 
than those associated with CTLA-4 inhibitors; however, grade 3–4 toxicities occur in about 
21% of immunotherapy cases [3, 4].
Monoclonal antibodies that are currently registered include the following: anti-PD-1 
(nivolumab and pembrolizumab), anti-PD-L1 (atezolizumab), and anti-CTLA-4 antibodies 
(ipilimumab) [5, 6].
2. Pathogenesis
The pathogenesis of irAEs is primarily based on and can be understood by the immune patho-
physiology that leads to hyperactivation of T-cells. PD-1 and CTLA-4 are immune check-
points that are expressed on the surface of antigen-presenting cells in the initiator and effector 
phase of T-cell activation, respectively. They are responsible for “switching off” the T-cell. 
Inhibition of these checkpoints allows for overexpression of the immune system, which is a 
powerful mechanism to defeat tumor cells.
Two signals are required by T cells to become fully activated [7]. The first signal origi-
nates from the interaction between T-cell receptors (TCR) and the antigen-peptide major-
histocompatibility complex (MHC), which contributes to the specificity of the immune 
response. Additionally, T cells require a costimulatory antigen-dependent signal that 
occurs through the interaction between CD28 on T cells and B7-1 and B7-2 on the antigen-
presenting cells (APC), to become entirely activated. On the other hand, expression of 
CTLA-4 by T cells constitutes a mechanism to prevent overstimulation of the immune 
system. CTLA-4 has a 100-fold higher affinity with the B7 complex than CD28, and this 
interaction is associated with an inhibitory function on the cell [8]. CTLA-4 inhibitors such 
as monoclonal antibodies ipilimumab and tremelimumab have been developed to block 
and release these breaks. Ipilimumab is currently approved for the treatment of metastatic 
malignant melanoma and is under investigation in the treatment of patients with nons-
mall cell cancer (NSCLC).
Another well-established mechanism of immune-response evasion is regulated by expres-
sion of PD-L1 in the malignant cells. PD-L1 binds to PD-1 on the T cells and thus initi-
ates a dual mechanism of inhibition by promoting apoptosis in antigen-specific T cells in 
lymph nodes and simultaneously reducing apoptosis in regulatory T cells referred to as 
T regs [9].
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The mechanism of defeating tumor cells can be understood by the three phases of immunoed-
iting [1]. The first phase, elimination, consists of the eradication of tumor cells by working 
with the innate and adaptive immune system. It activates several effector cells by inflam-
matory cytokines released by the tumor cells. The second phase, named equilibrium, is the 
development of resistance to the elimination phase by the tumour cells. Finally, the escape 
phase is where further resistance develops toward immune detection. The overactivation of 
the immune system, and blocking of suppressor checkpoints, also affects normal body tis-
sues, which is the possible mechanism by which toxicities arise, although this remains largely 
unknown [1]. Checkpoint inhibitors CTLA-4, PD-1, and PD-L1 blockers are approved for use 
in metastatic melanoma, nonsmall cell lung cancer (NSCLC), renal cell carcinoma, head and 
neck cancer, Hodgkin’s disease, and bladder cancer. They show improvement in overall sur-
vival in these tumor types.
3. irAEs’ general concepts
The incidence of grade 3 or 4 adverse events is higher with CTLA-4 blockers, and PD-1 
inhibitors appear to have better tolerability [2, 3, 10]. The grade of irAEs varies according to 
the dose of drug administered to patients, where smaller doses of drug are used, side effects 
are similar but are less frequent [11]. The incidence of irAEs can vary with tumor type and 
between different classes of drugs. The combination of PD-1 inhibitor with a CTLA-4 inhibi-
tor was recently approved for the treatment of metastatic malignant melanoma; however, 
more adverse reactions were seen when the two drugs were used together. In combina-
tion, there are especially more grade 3 or 4 events (55%). It is important to point out that 
although greater overall response rates were seen, it was also noted that the combination led 
to a higher incidence of severe irAEs and treatment discontinuations due to severe toxicity 
[12–14].
Generally, the most frequent irAEs are seen in the gastrointestinal (35%) and dermatological (44%) 
systems [11]. The incidence of hepatic and endocrine system involvement follows with about 
5–6%. Other systems less frequently affected are neurological, ophthalmological, pulmonary, renal, 
hematological, cardiovascular, respiratory, and musculoskeletal [3, 11, 13]. IrAEs typically develop 
within 6–12 weeks of initial dosing and resolution occurs within 12 weeks of onset. irAEs may 
develop after the first dose administered [15, 16]. It has been also hypothesized that the severity of 
the adverse correlates positively with a response to treatment [4, 14, 17]. However, the correlation of 
response to treatment and toxicity remains controversial. When managed correctly and promptly 
and with close monitoring, most are irAEs are reversible [11, 12, 14]. In general, the optimal man-
agement of irAEs includes early recognition (by far being the most important), proper assessment 
of severity so that the choice of therapy, either supportive or immunosuppressive, can be quickly 
and correctly implemented. Usually, mild adverse events can be observed or treated symptomati-
cally with supportive care. As a guide, with the exception of irAE endocrine moderate events, what 
is usually required is stopping the offending agent, implementing oral corticosteroid therapy, and 
restarting therapy again once symptoms have resolved. Severe irAEs warrant permanent discon-
tinuation of the drug, patient hospitalization, and high-dose intravenous corticosteroids, with slow 
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weaning. In very severe cases, other immunosuppressive agents such as infliximab or mycopheno-
late mofetil may be necessary [18].
In the following chapter sections, the different systems will be discussed.
3.1. Dermatological
A diffused, erythematous maculopapular rash and pruritus can occur in up to 50% of 
patients treated with anti-CTLA4 or up to 37% of patients treated with anti-PD-1 [4, 13, 15, 
17]. The rash can occur after the initial dose of treatment and can be ongoing (Figure 1A–C). 
However, symptoms on an average start 3–4 weeks after treatment. Vitiligo has also been 
reported [19, 20] (Figure 2). In severe cases, toxic epidermal necrolysis and Stevens-Johnson 
syndrome can occur, but in less than 1% of patients [15, 19]. Most of the dermatological 
eruptions and pruritus associated with these agents are managed symptomatically and usu-
ally do not require treatment delays or discontinuation. A recent meta-analysis of a total 
of 1208 patients demonstrated that the overall incidence of all-grade rash associated with 
ipilimumab was 24.3% (95% confidence interval [CI]: 21.4–27.6%), with a relative risk of 4.00 
(95% CI: 2.63–6.08, P < 0.001). The overall incidence of high-grade rash was 2.4% (95% CI: 
1.1–5.1%), with a relative risk of 3.31 (95% CI: 0.70–15.76, P = 0.13) [21]. A second meta-analy-
sis from a total of nine clinical trials in patients receiving ipilimumab, nivolumab, tremelim-
umab, pidlizumab, and pembrolizumab was included. The relative risk of all-grade rash was 
4.06 (95% CI: 3.35–4.91; P < 0.0001), vitiligo 16.3 (95% CI: 3.21–82.8; P = 0.0008), and pruritus 
was 3.4 (95% CI: 2.24–5.16; P < 0.00001) [22].
 Figure 1. Severe generalized maculo-papular rash associated with a combination of ipilimumab and nivolumab.
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Management
Topical glucocorticosteroids (e.g., betamethasone cream) or urea-containing creams in com-
bination with oral antipruritics (e.g., diphen-hydramine HCl or hydroxyzine HCl) are recom-
mended. The recommendation patients with a moderate rash, nonlocalized, and covers more 
than 50% of the skin surface area are to omit the offending agent. For grade 3 dermatological 
irAEs, hold treatment and administer a 3–4-week course of oral corticosteroids in the form of 
prednisone at a dose of 1 mg/kg or dexamethasone at a dose of 4 mg four times a day given 
orally daily. Treatment should be permanently discontinued for severe, life-threatening skin 
 Figure 2. Vitiligo associated with Ipilimumab.
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toxicity and prednisone at a dose of 1–2 mg/kg orally or equivalent formulations given at 
least for 30 days [23]. When a high-dose corticosteroid therapy is used, once symptoms are 
controlled, tapering of the steroids should occur over a one-month period at least [18]. Vitiligo 
may be associated with clinical benefit. Although it occurs in a small percentage of patients 
undergoing immunotherapy, there is a clear survival benefit in patients who do develop vit-
iligo during treatment [19, 20]. In some patients, vitiligo is associated with long-term survival 
[19, 20].
3.2. Gastrointestinal
Side effects can occur anywhere along the gastrointestinal tract, ranging from mucositis, aph-
thous ulcers, gastritis, and abdominal pain. More commonly, diarrhea related to colitis can be 
observed. This will be elaborated on in the next section [4, 13, 15].
3.2.1. Diarrhea and colitis
Diarrhea and colitis are very common side effects of checkpoint inhibitors. It is more fre-
quently seen when using CTLA-4 inhibitors than when using PDL-1 inhibitors. It is reported 
in about 30% of patients receiving CTLA-4 therapy, whereas it is as little as only 1–2% of 
patients receiving PDL-1 therapy [2, 4, 10, 24]. There is a higher incidence and a greater 
severity in grade when bigger doses are used as seen in the initial trials of ipilimumab when 
comparing 10 mg vs. 3 mg [4, 11, 24]. It is also more frequently seen and with a higher 
incidence in grade 3 and grade 4 events when the two checkpoint inhibitors are used in 
combination [2, 3, 12, 14]. This irAE is most likely to manifest within the first 6 weeks after 
checkpoint inhibitor therapy has been initiated, slightly later than dermatological irAEs, 
although this is not absolute, as it can also occur anywhere in the treatment course [15, 16, 
24]. Diarrhea, which is an increase in the frequency of stool is related to, but a different 
clinical entity from colitis. The CTCAE states that symptoms related to colitis are associated 
with abdominal pain and include patients who have blood or mucus in their stool. If there 
is evidence of inflammation on endoscopic investigation or radiographically, it is also then 
defined as colitis. It is important to exclude other infectious causes of diarrhea, for instance, 
Clostridium difficile infection in all cases [4, 13, 15]. In very selected cases, where patients have 
accompanying symptoms of high fevers, leukocytosis, and those who have been on immu-
nosuppressive therapy for long periods of time rendering them more susceptible to infec-
tions, prophylactic antibiotics can be considered [15]. A colonoscopy can be considered in 
patients with severe or persistent symptoms or if the cause is unclear [13, 15, 24] (Figure 3).
In severe conditions, perforation can occur and lead to death and must be excluded in patients 
with symptoms of peritonitis. These patients may require surgery and possible colostomy [3, 15].
Mild symptoms can be treated symptomatically with rehydration, replacing electrolyte losses, 
and loperamide [3, 4, 18, 24]. Grade 2 irAEs require the offending immunotherapy agent to 
be omitted. If symptoms are ongoing for more than one week, there should be an immediate 
commencement of oral corticosteroid therapy at a dose of 1 mg/kg/day. When symptoms are 
resolved, the immunotherapy drug can be recommenced [4, 6, 13, 15, 24].
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Severe or life-threatening colitis and symptoms consistent with perforation, ileus, or fever is 
a serious complication. High-dose intravenous corticosteroids commencing at a starting dose 
of 2 mg/kg/day must be initiated promptly [15, 18].
If symptoms persist, a single dose of immunosuppressive infliximab therapy at 5 mg/kg must 
be considered unless there is a contraindication [15, 18, 24]. The dose of infliximab be repeated 
after 2 weeks if symptoms persist [13, 15, 24]. Mycophenolate mofetil can also be considered 
in severe and refractory cases [15]. The most important part of management of a patient with 
colitis is recognition and early initiation of aggressive treatment. Diarrhea treatment guide-
lines have been shown to reduce bowel perforation and colectomy rates and serious irAEs by 
up to 50% when this is done. There is anecdotal evidence that shows that high-dose therapy 
initiated for irAEs does not affect efficacy of treatment [2, 12]. Furthermore, it is postulated 
that the severity of the adverse event correlates with a better response to treatment [11, 14, 17].
3.3. Hepatic
Hepatotoxicity can be observed following treatment with anti-CTLA4 or anti-PD-1/anti-PDL1 
therapy usually at about 6 weeks after initiation. It frequently manifests as an asymptomatic 
increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or total 
bilirubin. Hepatotoxicity has been observed in 3–9% of patients receiving ipilimumab [25, 26]. 
A meta-analysis of a total of nine randomized controlled trials in patients with solid tumors 
 Figure 3. Severe colitis associated with ipilimumab.
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demonstrated that the use of PD-1 inhibitors, when compared to the control group of che-
motherapy or everolimus, significantly increased the risk of developing all, but high-grade 
hepatic AEs. Additionally, the risk of all grades of hepatic AEs was considerably higher when 
a nivolumab and ipilimumab combination was used compared to ipilimumab monotherapy. 
No significant differences in the risk of all-grade and high-grade hepatic irAEs were found 
between PD-1 inhibitors monotherapy and ipilimumab monotherapy [27].
3.3.1. Management
The differential diagnosis of immune-related hepatotoxity includes progressive metastatic 
liver disease, viral hepatitis, or another drug-specific toxic reaction. Diagnostic workup 
includes viral hepatitis studies, liver imaging, and excluding other drug-related causes for 
abnormal liver functions. A liver biopsy is indicated when the etiology is unclear [15]. It is 
important to point out that hepatic toxicity can occur in the absence of symptoms. Baseline 
liver functions should be obtained before commencement of therapy [15, 18]. When derange-
ments are documented, other infectious causes, concurrent medications used by patients and 
disease progression must be excluded by appropriate investigations [15, 18].
Severe hepatotoxicity requires permanent discontinuation of the drug. Additionally, high-dose 
intravenous glucocorticosteroids for 24–48 hours followed by an oral steroid taper with dexa-
methasone at a dose of 4 mg every 4 hours or prednisone at 1–2 mg/kg tapered over not less 
than 30 days. If the levels of serum transaminase do not decrease 48 hours after commencement 
of systemic steroids, oral mycophenolate mofetil 500 mg every 12 hours should be considered 
[28]. Infliximab is associated with hepatotoxicity and should be avoided in this clinical setting.
3.4. Endocrine
Endocrine irAEs are in general inconstantly described in recent published data. Assessment 
and reporting of endocrine irAEs in clinical trials should be done using standardized diag-
nostic criteria and terminology. Unfortunately, as a consequence of the lack of standardiza-
tion, the true incidence of endocrine adverse events on patients undergoing anti-CTLA-4 and 
antiPD-1/PD-L1 pathway blockades is unknown. Thyroid dysfunction is the most common 
irAE reported. Hypophysitis has merged as a distinctive side effect of CTLA-4-blocking anti-
bodies [2, 13, 29]. The spectrum of endocrine disease in patients treated with ipilimumab 
includes hypophysitis, and occasionally primary adrenal insufficiency. This complication, 
if not promptly diagnosed, can be life-threatening (due to secondary hypoadrenalism). 
Hypopituitarism caused by CTLA-4-blocking antibodies is rarely reversible, and prolonged 
or lifelong hormonal replacement treatment is often required. The mechanism of injury and 
pathogenesis to the endocrine system triggered by ipilimumab needs to be clarified.
Presenting symptoms of hypothyroidism, such as fatigue, weakness, depression, memory 
loss, cold intolerance, and cardiovascular abnormalities, may be incorrectly attributed to the 
primary malignant disease. The onset of hypothyroidism is variable and can occur within 
the first 5 months and up to 2 years following immune-therapy. Some patients may develop 
autoimmune thyroiditis [30]. The prevalence of abnormal thyroid tests in one series was 15% 
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[31]. A recent meta-analysis of ten clinical trials showed that relative risk of all grades hypo-
thyroidism 8.26 (95% CI: 4.67–14.62; P < 0.00001), hyperthyroidism 5.48 (95% CI: 1.33–22.53; 
P = 0.02), hypophyisitis 22.03 (95% CI: 8.52–56.94; P < 0.00001), and adrenal insufficiency 3.87 
(95% CI: 1.12–13.41; P = 0.03) [32].
Baseline thyroid function tests are also recommended. Pituitary hormones, in the presence of 
symptoms, are indicated if thyroid functions are normal. Primary adrenal and primary pitu-
itary insufficiency can be differentiated with an early morning cortisol [4, 13, 15]. MRI can be 
obtained to visualize the pituitary gland to confirm the diagnosis of hypophysitis [4, 15]. MRI 
findings can be nonspecific, but can show a general enlargement of the pituitary gland [33, 
34]. In a review, about 85% of patients had pituitary gland abnormality on MRI [5]. Treatment 
of hypothyroidism usually requires replacement of thyroid hormone, and in mild cases of 
adrenal insufficiency, oral corticosteroid therapy can be used [4, 8]. Adrenal insufficiency or 
crisis is a medical emergency. This warrants hospitalization, high-dose intravenous cortico-
steroids with mineralocorticoid activity. Infection or sepsis should be excluded in these cases. 
A consultation with an endocrinologist is needed to ascertain if long-term hormone replace-
ment is necessary [13, 15, 18].
3.5. Pulmonary
Immune-related pneumonitis is a serious IrAE associated with immunotherapy. This is more 
common with PD-1 blockers, although the incidence is <1% and presents far later into treat-
ment phase [13]. Patients undergoing immunotherapy, experiencing new symptoms of cough 
or dyspnea, should arouse suspicion for the development of pneumonitis (Figure 4). In a 
nivolumab monotherapy, early dose-finding study (CA209-003) that evaluated various tumor 
types, three treatment-related deaths (1%) due to pneumonitis were reported in two patients 
with NSCLC and one patient with colorectal cancer [36]. A recent meta-analysis of 11 clinical 
trials showed that the odds ratio was 3.96 (95% confidence interval [CI]: 2.02–7.79; P < 0.0001) 
for all-grade pneumonitis and 2.87 (95% CI: 0.90–9.20; P = 0.08) for high-grade pneumonitis. 
Additionally, the odds ratio of all grades of pneumonitis with a nivolumab and ipilimumab 
combination vs. ipilimumab monotherapy was 3.68 (95% CI: 1.59–8.50; P = 0.002), and for 
high-grade pneumonitis, it was 1.86 (95% CI: 0.36–9.53; P = 0.46). Subgroup analysis did not 
demonstrate a significant difference between lung cancer patients and other types of cancer 
in the risk of pneumonitis. This is an irAE that can occur both with anti-CTLA-4 or anti-
PD-1 agents. It has been reported in approximately 1% of patients treated with anti-PD-1 
agents and occurs more frequently than with anti-CTLA-4 agent ipilimumab. Deaths related 
to immune-onset pneumonitis have been reported in NSCLC patients. Pneumonitis manage-
ment involves prompt initiation of high-dose corticosteroids, close symptoms monitoring, 
and oxygen requirements. Immunosuppressive interventions may be required in a minority 
of patients [37]. Radiological findings should be monitored closely.
A second meta-analysis comprised 20 PD-1 inhibitor trials in 4496 patients with malignant 
melanoma (12 trials), NSCLC (5 trials), and RCC (3 trials). The overall incidence of pneumonitis 
during PD-1 inhibitor monotherapy was 2.7% (95% CI, 1.9–3.6%) for all-grade and 0.8% (95% CI, 
0.4–1.2%) for grade 3 or higher pneumonitis. The incidence was higher in NSCLC for all-grade 
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(4.1 vs. 1.6%; P = 0.002) and grade 3 or higher pneumonitis (1.8 vs. 0.2%; P < 0.001) compared 
with melanoma. The incidence in RCC was higher than in melanoma for all grades of pneu-
monitis (4.1 vs. 1.6%; P < 0.001) but not for grade 3 or higher. Four pneumonitis-related deaths 
were documented in patients with NSCLC in the monotherapy group. Pneumonitis was more 
frequent during combination immunotherapy than monotherapy for all grades (6.6 vs. 1.6%; 
P < 0.001) and for grade 3 or higher (1.5 vs. 0.2%; P = 0.001) in melanoma, with one pneumonitis-
related death during combination therapy. Multivariable analyses demonstrated higher odds 
of pneumonitis in NSCLC for all-grade (odds ratio [OR], 1.43; 95% CI, 1.08–1.89; P = 0.005) and 
grade 3 or higher pneumonitis (OR, 2.85; 95% CI, 1.60–5.08; P < 0.001) and in RCC for all-grade 
pneumonitis (OR, 1.59; 95% CI, 1.32–1.92; P < 0.001) compared with melanoma. The combina-
tion therapy had significantly higher odds than monotherapy for all-grade (OR, 2.04; 95% CI, 
1.69–2.50; P < 0.001) and grade 3 or higher pneumonitis (OR, 2.86; 95% CI, 1.79–4.35; P < 0.001). 
The authors concluded that the incidence of PD-1 inhibitor-related pneumonitis was higher in 
NSCLC and RCC and during combination therapy [38].
Several pulmonary inflammatory conditions have also been seen in patients treated with ipili-
mumab, including sarcoidosis [39, 40] and organizing inflammatory pneumonia [41].
In any patient undergoing anti-CTLA-4 or anti-PD-1/PD-L1 immunotherapy, presenting with 
pulmonary symptoms, such as an upper respiratory infection, new cough, or shortness of 
breath, pneumonitis should be considered and evaluated with imaging. Because the onset and 
Figure 4. Pneumonitis associated with Nivolumab.
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symptoms of pneumonitis are often vague and diagnosis is often delayed, clinicians should 
be aware of this and consider diagnostic radiology (X-rays, CT scans) early. Bronchoscopy 
and lung biopsy should be considered to rule out other causes such as infectious etiologies 
before starting treatment, especially in moderate-to-severe cases [13, 15]. Differential diag-
nosis includes disease progression of cancer, lymphangitis carcinomatosis, opportunistic 
infections, severe pneumonitis, early cardiac failure, alveolar hemorrhage, or congestive car-
diac failure. In severe cases, treatment should comprise high doses of corticosteroids such as 
intravenous methylprednisone at a dose of 2 mg/kg. Additional immunosuppression with 
infliximab, mycophenolate mofetil, or cyclophosphamide may be required and is a reasonable 
approach in nonresponding patients [13, 15].
3.6. Ophthalmological
Ophthalmological immune-related adverse events are extremely rare and occur in less than 
1% of patients treated with anti-CTLA-4 therapy. The incidence with anti-PD-1 antibodies is 
unknown [42, 43]. Besides, from the direct toxicity of immunotherapy agents, the eye can also 
indirectly be affected via other immune-related adverse endocrinopathies such as hyperthy-
roidism form autoimmune thyroiditis [30, 43]. There have been case reports of Grave’s opthal-
mopathy with symptoms and signs of proptosis associated with swelling of extraocular muscles 
and xeropthalmia [30, 42, 44]. Ophthalmological side effects include episcleritis, conjunctivitis, 
and uveitis [3]. A rare case of bilateral iridocyclitis and of bilateral choroidal neovascularization 
was reported [4, 42, 45]. Most cases can be managed with topical corticosteroids [34]. Systemic 
corticosteroids can be implemented in patients who do not respond to topical management or 
in grade 3 or in grade 4 cases. It is always recommended to consult an opthalomologist [43].
3.7. Neurological
Neurological symptoms can vary widely and present as a range of different conditions. It 
is postulated that neurological toxicity can occur in about 1–3% of patients from literature 
reviews [46]. Most information collected about neurological toxicity from immunotherapy 
is from case reports. Posterior reversible encephalopathy syndrome, Guillain-Barre, asep-
tic meningitis, enteric neuropathy, and transverse myelitis cases have been reported [4, 13]. 
There have also been isolated reports of chronic inflammatory demyelinating polyneuropathy 
and a Myasthenia-Gravis type syndrome [47]. Most times, if the adverse event is low-grade, 
stopping the offending agent until symptoms dissipate suffices or commencing low-dose oral 
corticosteroids [18, 47]. In grade 3 or grade 4 events, high-dose intravenous corticosteroids 
are warranted, and at times, plasmapheresis and intravenous immunoglobulin are warranted 
[4, 13]. It is worthwhile to involve neurologists to assist with diagnosis and what treatment is 
necessary for each individual case according to severity [4, 13].
3.8. Hematological
The evidence regarding hematological side effects is all anecdotal and based on case reports 
as well. Severe anemia requiring transfusions and febrile neutropenia requiring support 
Management and Supportive Care of Patients Undergoing Immunotherapy
http://dx.doi.org/10.5772/67372
39
with granulocyte colony stimulating factor (GCSF) may occur [4, 48]. One case reported a 
patient with neutropenia receiving a CTLA-4 inhibitor that was refractory to GCSF therapy 
and required immunoglobulin therapy [49]. Red cell aplasia, acquired hemophilia A, and 
thrombocytopenia have all been described as well [4, 13]. Recently, cases of hemolytic-uremic 
syndrome occurring in a patient receiving ipilimumab have been reported [50]. Generally, 
hematological immune-related adverse events respond to steroid therapy, but in severe cases, 
may need more intense therapy.
3.9. Renal
Renal toxicity due to checkpoint inhibitors is extremely rare. A case series of thirteen patients 
provides information of different clinical presentations of patients with immune-related nephri-
tis and different histological diagnoses [51]. It showed that the median time to develop kidney 
injury from immune checkpoint inhibitors was around 91 days though it ranged widely. It is 
estimated that about 1–2% of patients can have acute kidney injury from checkpoint inhibitors, 
with less than 1% of those patients having a serious grade 3 or 4 events [15, 51]. Histology in 
these patients showed a dominance of tubule-interstitial nephritis, and in one patient, showed a 
thrombotic microangiopathy [51, 52]. Initiating corticosteroid early therapy and stopping drug 
is the recommended treatment for acute kidney injury/interstitial nephritis from checkpoint 
inhibitor therapy. Most patients respond to steroid therapy [15]. Other causes of kidney injury 
such as infection or other medications should be excluded, and when etiology is in doubt, a 
renal biopsy should always be performed if not contraindicated. Close monitoring of patient’s 
serum creatinine should be followed during treatment, especially if there is even a slight 
increase in creatinine. Grade 1 toxicity according to management guidelines is defined as an 
increase in creatinine up to 1.5 times above baseline, grade 2 or grade 3, defined as a creatinine 
above 1.5 times above baseline to 6 times above normal. Grade 4 events are life-threatening [15]. 
Mycophenolate Mophetil in refractory cases can be considered and potentially anti-TNF agents 
[51]. Data regarding management in these patients is very limited, and general supportive 
measure should be carried out as well such as fluid therapy and correcting electrolytes. Early 
involvement with a nephrologist is recommended as there were dialyses-requiring patients in 
the series as well [15, 51].
3.10. Pancreatitis
There have been reports of elevated amylase and lipase levels in clinical trials with unknown 
clinical significance. It is not recommended in general guidelines to monitor pancreatic enzymes 
unless there is a clinical suspicion of active or acute pancreatitis. There have been very few 
case reports of patients who developed fulminant pancreatitis. General guidelines for immune-
related adverse events should be followed with close monitoring in these patients [15, 43, 53].
3.11. Cardiac
This is also extremely rare. There are case reports of varying cardiac conditions in patients 
with toxicity form checkpoint inhibitors. In a series, eight cases of immune-related cardiac 
toxicity were reviewed. Patients were asymptomatic of any cardiac-related issues before 
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initiating treatment with checkpoint inhibitors. Cases ranged from myocarditis and cardio-
myopathy that responded well to corticosteroid therapy as well as cases that were fatal and 
refractory to treatment. Myocardial fibrosis was found in one patient’s autopsy findings, in 
combination with multiorgan failure. The patients in this series were both very young and 
very old with no cardiac history and included patients with predisposing cardiac dysfunc-
tion. A patient also suffered a cardiac arrest. A total of 63% of patients had other organ sys-
tems involved in combination with the cardiac toxicity [54]. The review can allude to many 
hypotheses about cardiac related toxicity. There is a possibility of higher risk to develop 
cardiac toxicity if there are predisposing conditions and a higher incidence if there are other 
systems involved. As with other rare irAEs, more prospective data are needed. More case 
reports are emerging and include fulminant myocarditis and pericardial effusions with 
tamponade [55, 56]. It is clear that treating physicians need to be aware of the possibility of 
this irAEs and to start treatment with supportive and corticosteroid therapy promptly to 
avoid serious complications and death. There is currently no recommendations regarding 
monitoring of cardiac enzymes during therapy [54].
4. Conclusion
When managing a patient with suspected irAEs, the patients should be treated as individuals, 
and a thorough workup of each side effect should be done to ascertain whether or not there 
is truly an irAE and not other treatable causes. Most importantly, a high index of suspicion 
must always be kept in mind even though most are self-limiting and low-grade in severe cases 
if treatment is not given promptly and correctly, it can be life-threatening and result in death. 
Early recognition and aggressive treatment with immunosuppression is vital to prevent mor-
bidity and mortality.
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